The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study

Anesthesia Clinical Trial

— TECHNO-MULTI  

Official title:

The Clinical Significance of Portal Hypertension After Cardiac Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03656263
• Other study ID #: TECHNO-MULTI
• Status: Completed
• Start date: November 14, 2018
• Est. completion date: February 20, 2021

Study information

• Verified date: February 2021
• Source: Montreal Heart Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Portal flow pulsatility detected by Doppler ultrasound is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse outcomes based on previous studies performed at the Montreal Heart Institute. This multicenter prospective cohort study aims to determine if portal flow pulsatility after cardiopulmonary bypass separation is associated with a longer requirement of life support after cardiac surgery.

Description:

Hypothesis: Portal flow pulsatility detected by Doppler ultrasound during cardiac surgery is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse clinical outcomes. Background: Peri-operative right ventricular failure is associated with a high mortality rate. In this context, organ perfusion is hampered by both the reduction of cardiac output and venous congestion from the elevation of central venous pressure. The clinician's objective is to appreciate the hemodynamic impact on end-organs in an effort to adjust the therapy accordingly since the ultimate goal is to optimize their perfusion. Based on this rationale, organ specific blood flow assessment using Doppler ultrasound could be used to personalize management. In order to non-invasively assess the presence of cardiogenic portal hypertension, Doppler ultrasound can be used to detect portal flow pulsatility, an abnormal variation in the velocity of blood flow within the main portal vein. In two single-center cohort studies, the presence of portal flow pulsatility after cardiac surgery was independently associated with post-operative complications such as major bleeding, acute kidney injury (AKI) and delirium as well as increased length of intensive care unit (ICU) stay. Specific Objectives: This multi-center cohort study aim to determine whether the association between portal flow pulsatility and organ dysfunction seen in previous studies is present across multiple cardiac surgery centers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 360
• Est. completion date: February 20, 2021
• Est. primary completion date: February 20, 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients (=18 years old) and able to give informed consent undergoing cardiac surgery with the use of CPB for whom peri-operative TEE is planned.
• High surgical risk defined as at least one of the following:

1. Multiple surgical procedures planned

2. EuroSCORE II = 5%

3. Known pulmonary hypertension (mPAP>25mmHg or sPAP>40mmHg).

Exclusion Criteria:

• Patient with a critical pre-operative state defined as vasopressor requirement, mechanical circulatory support, dialysis, mechanical ventilation or cardiac arrest necessitating resuscitation.
• Patient with known condition that could interfere with portal flow assessment or interpretation (liver cirrhosis, portal vein thrombosis)
• Planned cardiac transplantation
• Planned ventricular assist device implantation

Related Conditions & MeSH terms

• Anesthesia
• Congestive Heart Failure
• Heart Failure
• Hyperemia
• Hypertension
• Hypertension, Portal
• Right Heart Failure
• Surgery--Complications
• Venous Congestion

Intervention

Diagnostic Test:
• Doppler assessment of portal vein flow
Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.

Locations

Country	Name	City	State
Canada	Montreal Heart Institute	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Montreal Heart Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of invasive life support after cardiac surgery. (Tpod)	Defined as the time of Persistent Organ Dysfunction (POD) or Death	Up to 28 days
Secondary	All cause death	Death from any cause	Up to 28 days
Secondary	Acute kidney injury according to KDIGO serum creatinine criteria	Stage 1: =50% or 27 umol/L increases in serum creatinine Stage 2: =100% increase in serum creatinine Stage 3 =200% increase in serum creatinine or an increase to a level of =254 umol/L or dialysis initiation.	Up to 28 days
Secondary	Major bleeding defined by the Bleeding Academic Research Consortium (BARC)	Perioperative intracranial bleeding within 48h Reoperation after closure of sternotomy for the purpose of controlling bleeding Transfusion of =5 units of whole blood of packed red blood cells within a 48 hours period Chest tube output =2L within a 24 hours period	Up to 28 days
Secondary	Surgical reintervention for any reasons	Re-operation after the initial surgery for any cause	Up to 28 days
Secondary	Deep sternal wound infection or mediastinitis	Diagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician.	Up to 28 days
Secondary	Delirium	Defined as a intensive care delirium screening checklist (ICDSC) score of =4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU)	Up to 28 days
Secondary	Stroke	A central neurologic deficit persisting longer than 72 hours	Up to 28 days
Secondary	Total duration of ICU stay in hours	Number of hours passed in the ICU	Up to 28 days
Secondary	Duration of hospital stay (in days)	Number of days hospitalized from the day of surgery to discharge	Up to 28 days
Secondary	Duration of mechanical ventilation (in hours)	Number of hours of mechanical ventilation	Up to 28 days
Secondary	A composite outcome of major morbidity or mortality (41): including death, prolonged ventilation, stroke, renal failure (Stage =2), deep sternal wound infection and reoperation for any reason.	Composite endpoint after cardiac proposed by the Society of Thoracic Surgeons	Up to 28 days